Raphael Amit - Allovir External Director

ALVR
 Stock
  

USD 7.85  0.46  5.54%   

  Director
Professor Raphael Amit is External Director of Alvarion Ltd. Prior to joining the board of Directors Professor Amit served as Chairman of the board of Directors of Creo Products Inc until May 2005. Professor Amit was the Robert B. Goergen Professor of Entrepreneurship and a Professor of Management at the Wharton School of the University of Pennsylvania since July 1999. Professor Amit also serves as the Academic Director of Whartons Goergen Entrepreneurial Management Programs. Prior thereto Professor Amit was the Peter Wall Distinguished Professor at the Faculty of Commerce and Business Administration University of British Columbia where he was the founding director of the W. Maurice Young Entrepreneurship and VC Research Center. From 1983 to 1990 Professor Amit served on the faculty of the J.L. Kellogg Graduate School of Management at Northwestern University where he received the J.L. Kellogg Research Professorship and the Richard M. Paget Research Chair in Business Policy. Professor Amit holds B.A. and M.A. degrees in Economics both from The Hebrew University of Jerusalem and a Ph.D. in Management from the Northwestern Universitys J.L. Kellogg Graduate School of Management. Professor Amit has served as a consultant to a range of organizations in North America and Europe on strategic entrepreneurial management and new venture formation issues.
Age: 64  Director Since 2003      
617 433 2605  https://www.allovir.com

Allovir Management Efficiency

Allovir has return on total asset (ROA) of (39.1) % which means that it has lost $39.1 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (70.84) %, meaning that it created substantial loss on money invested by shareholders. Allovir management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 23.13 M in liabilities with Debt to Equity (D/E) ratio of 0.12, which may suggest the company is not taking enough advantage from borrowing. Allovir has a current ratio of 10.86, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Allovir until it has trouble settling it off, either with new capital or with free cash flow. So, Allovir's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Allovir sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Allovir to invest in growth at high rates of return. When we think about Allovir's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing few of many executives

DIRECTOR Since

John CraigLundin Mng Corp
2018
Lydia KennardFreeport-Mcmoran
2013
Peter CassidyMmg
2010
Maree ArnasonSandfire Resources NL
2015
Andrew LanghamFreeport-Mcmoran
2015
Jon MadonnaFreeport-Mcmoran
2007
Catherine StefanLundin Mng Corp
2015
Courtney MatherFreeport-Mcmoran
2015
Jiqing XuMmg
2019
Peter JonesLundin Mng Corp
2013
Xiaoyu GaoMmg
2018
Jennifer SeabrookMmg
2015
Richard PoultonCalifornia-Engels Mining Co
1993
Robert ScottSandfire Resources NL
2010
Cheuk LeungMmg
2012
Dustan McCoyFreeport-Mcmoran
2021
Frances TownsendFreeport-Mcmoran
2013
David JointFreeport-Mcmoran
N/A
Soocheol ShinSandfire Resources NL
2012
Roric SmithSandfire Resources NL
2016
Jian JiaoMmg
2018
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell therapies to prevent and treat devastating viral-associated diseases. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts. Allovir operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 110 people. Allovir (ALVR) is traded on NASDAQ Exchange in USA and employs 110 people.

Allovir Leadership Team

Elected by the shareholders, the Allovir's board of directors comprises two types of representatives: Allovir inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Allovir. The board's role is to monitor Allovir's management team and ensure that shareholders' interests are well served. Allovir's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Allovir's outside directors are responsible for providing unbiased perspectives on the board's policies.
Doron Inbar, Non-Executive Independent Director
Raphael Amit, External Director
Zeev Farkash, Executive Vice President - Sales
Assaf Katan, Acting President and CEO
Moshe Fourier, Executive Vice President-R&D
Tali Aben, Non-Executive Independent Director
Mati Wax, CTO
Avi Stern, CFO
Amnon Yacoby, Independent Chairman of the Board
Nir Golan, Executive Vice President
Ziv Eizenberg, Executive Vice President-Human Resources
Leor Porat, Executive Vice President General Counsel

Allovir Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Allovir a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Allovir in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Allovir's short interest history, or implied volatility extrapolated from Allovir options trading.

Pair Trading with Allovir

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allovir position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allovir will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Allovir could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allovir when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allovir - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allovir to buy it.
The correlation of Allovir is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allovir moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allovir moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allovir can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Please continue to Trending Equities. You can also try Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Complementary Tools for analysis

When running Allovir price analysis, check to measure Allovir's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allovir is operating at the current time. Most of Allovir's value examination focuses on studying past and present price action to predict the probability of Allovir's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Allovir's price. Additionally, you may evaluate how the addition of Allovir to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Is Allovir's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allovir. If investors know Allovir will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allovir listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Allovir is measured differently than its book value, which is the value of Allovir that is recorded on the company's balance sheet. Investors also form their own opinion of Allovir's value that differs from its market value or its book value, called intrinsic value, which is Allovir's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allovir's market value can be influenced by many factors that don't directly affect Allovir's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allovir's value and its price as these two are different measures arrived at by different means. Investors typically determine Allovir value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allovir's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.